With Large Biosimilars Opportunity In Sight, Multinational Companies Open Dialogue With India’s Wockhardt
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Adversities are throwing up unexpected opportunities for the debt-ridden Indian drug maker Wockhardt. While the company is being helped to tide over its unprecedented financial crisis of $600 million in debts by a group of large Indian banks, strategic opportunities in its biotech businesses have now come to surface
You may also be interested in...
Wockhardt In Final Stages Of Talks To Sell German Operation To Lindo Pharm
MUMBAI - Financially troubled Indian drug maker Wockhardt is close to selling Esparma - its German operation - to Lindo Pharm, a privately held German company specializing in thyroid preparations and antibiotics
Wockhardt In Final Stages Of Talks To Sell German Operation To Lindo Pharm
MUMBAI - Financially troubled Indian drug maker Wockhardt is close to selling Esparma - its German operation - to Lindo Pharm, a privately held German company specializing in thyroid preparations and antibiotics
Investment Bank Rothschild Indicates Several Strong Points Of Cash-strapped Wockhardt
MUMBAI - Indian pharmaceutical and biotechnology company Wockhardt may be finding itself in an extremely tight financial condition due to its commitment to repay $110 million foreign currency convertible bonds by October and debts of more than $600 million it took for overseas acquisitions; however analysts remain upbeat on company strengths